H.B. Fuller appoints former J&J MedTech executive Celine Martin to board

FULLER H B CO

Celine Martin, 51, elected as Class III director effective Dec. 1, 2025, serving on Audit and Compensation Committees.
Martin most recently served as Company Group Chairman, Cardiovascular & Specialty Solutions at Johnson & Johnson MedTech (2022–2025).
Appointment supports H.B. Fuller's strategic expansion into high-margin medical adhesives and goal of >20% EBITDA margin.
Board size increases to nine directors, eight independent; Martin receives $100K cash retainer and 1,300 RSUs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.